LEI-106

Overview

LEI-106 is a dual ABHD6 and DAGL-α inhibitor, with a K i of 0.8 μM for ABHD6, and an IC 50 of 18 nM and a K i of 0.7 μM for DAGL-α. LEI-106 blocks the synthesis of 2-arachidonoylglycerol, reduces the level of endothelial cell-derived 2-arachidonoylglycerol, without altering the levels of cannabinoids and diacylglycerol. LEI-106 is applicable to research related to diet-induced obesity and metabolic syndrome.

Application

Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Obesity | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > MAGL | Products > Signaling Pathways > DAGL

Product Information

• Catalog No.: HY-124314
• CAS No.: 1620582-23-1
• Molecular Formula: C26H27NO6S
• Molecular Weight: 481.56
• Purity: 98.86%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source